Immune Pathophysiology of Aplastic Anemia
Acquired aplastic anemia (AA) is considered an immune-mediated disease because approximately 70% of AA patients improve with immunosuppressive therapy. However, little is known about the inciting antigens or the mechanisms responsible for the destruction of hematopoietic stem cells by immune system attack. Recent advances in immunologic techniques have promoted our understanding of the pathogenesis of AA and have provided evidence that AA is an organ-specific T-cell-mediated disease localized in the bone marrow. Moreover, antibody screening of patients’ serum with a complementary DNA library derived from hematopoietic cells has identified several proteins as candidate autoantigens in AA.
Key wordsAplastic anemia T-cell repertoire Autoantigen Paroxysmal nocturnal hemoglobinuria
Unable to display preview. Download preview PDF.
- 3.Bacigalupo A, Bruno B, Saracco P, et al, for the European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO). Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. Blood. 2000;95:1931–1934.PubMedGoogle Scholar
- 8.Sugimori C, Chuhjo T, Wang H, Feng X, Nakao S. Roles of HLA-DR15 alleles in the immune mechanisms of acquired aplastic anemia: methods of contribution differ between DRB1*1501 and DRB1*1502 [abstract]. Blood. 2003;102:508a.Google Scholar
- 25.Papadaki HA, Kritikos HD, Valatas V, Boumpas DT, Eliopoulos GD. Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factor-α antibody therapy. Blood. 2002;100:474–482.CrossRefPubMedGoogle Scholar